Literature DB >> 3524819

Loss of a c-H-ras-1 allele and aggressive human primary breast carcinomas.

C Theillet, R Lidereau, C Escot, P Hutzell, M Brunet, J Gest, J Schlom, R Callahan.   

Abstract

The human H-ras protooncogene was shown to be expressed in 16 of 22 invasive ductal carcinomas of the breast. The K- and N-ras protooncogenes were either not expressed or expressed at low levels. No amplification or rearrangement of the three ras genes was detected among the 104 breast carcinoma DNAs tested. These results indicate that the overexpression of H-ras in human breast tumors is not correlated with alteration of the protooncogene. In addition, we did not find any point mutation at the codon 12 of the H-ras or K-ras protooncogenes in 32 and 64, respectively, tumor DNAs examined. However, in tumor DNAs from 14 of 51 patients, heterozygous for H-ras-1 related BamHI restriction fragments, one allele was lost. This allele loss did not alter ras Mr 21,000 protein expression. Correlation with clinicopathological data showed, however, that the loss of one H-ras-1 allele in breast carcinoma DNAs is significantly linked to histological Grade III tumors, the lack of estrogen and/or progesterone receptors, and the subsequent occurrence of distal metastasis. Our results thus indicate that the loss of one H-ras-1 allele correlates with the most aggressive primary carcinomas of the breast.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3524819

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

1.  Mapping of 262 DNA markers into 24 intervals on human chromosome 11.

Authors:  A Tanigami; T Tokino; S Takiguchi; M Mori; T Glaser; J W Park; C Jones; Y Nakamura
Journal:  Am J Hum Genet       Date:  1992-01       Impact factor: 11.025

2.  Isolation and mapping of 62 new RFLP markers on human chromosome 11.

Authors:  T Tokino; E Takahashi; M Mori; A Tanigami; T Glaser; J W Park; C Jones; T Hori; Y Nakamura
Journal:  Am J Hum Genet       Date:  1991-02       Impact factor: 11.025

3.  Characterization of the human p57KIP2 gene: alternative splicing, insertion/deletion polymorphisms in VNTR sequences in the coding region, and mutational analysis.

Authors:  T Tokino; T Urano; T Furuhata; M Matsushima; T Miyatsu; S Sasaki; Y Nakamura
Journal:  Hum Genet       Date:  1996-05       Impact factor: 4.132

Review 4.  A model to account for the effects of oncogenes, TPA, and retinoic acid on the regulation of genes involved in metastasis.

Authors:  J Pohl; A Radler-Pohl; V Schirrmacher
Journal:  Cancer Metastasis Rev       Date:  1988-12       Impact factor: 9.264

5.  Distribution of Ha-RAS-1 proto-oncogene alleles in breast cancer patients and in a control population.

Authors:  G Saglio; C Camaschella; M Giai; A Serra; A Guerrasio; B Peirone; P Gasparini; U Mazza; R Ceppellini; N Biglia
Journal:  Breast Cancer Res Treat       Date:  1988-05       Impact factor: 4.872

Review 6.  Genetic alterations in primary breast cancer.

Authors:  R Callahan
Journal:  Breast Cancer Res Treat       Date:  1989-07       Impact factor: 4.872

7.  Three tumor-suppressor regions on chromosome 11p identified by high-resolution deletion mapping in human non-small-cell lung cancer.

Authors:  G Bepler; M A Garcia-Blanco
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

8.  Human mammary cancer progression model recapitulates methylation events associated with breast premalignancy.

Authors:  Nancy Dumont; Yongping G Crawford; Mahvash Sigaroudinia; Shefali S Nagrani; Matthew B Wilson; Gertrude C Buehring; Gulisa Turashvili; Samuel Aparicio; Mona L Gauthier; Colleen A Fordyce; Kimberly M McDermott; Thea D Tlsty
Journal:  Breast Cancer Res       Date:  2009-12-08       Impact factor: 6.466

9.  Characterization of a panel of somatic cell hybrids for subregional mapping along 11p and within band 11p13. Subdivision of the WAGR complex region.

Authors:  P Couillin; M Azoulay; I Henry; N Ravisé; M C Grisard; C Jeanpierre; F Barichard; P Metezeau; J J Candelier; W Lewis
Journal:  Hum Genet       Date:  1989-05       Impact factor: 4.132

10.  Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer.

Authors:  Joseph A Sparano; Stacy Moulder; Aslamuzzaman Kazi; Domenico Coppola; Abdissa Negassa; Linda Vahdat; Tianhong Li; Christine Pellegrino; Susan Fineberg; Pam Munster; Mokenge Malafa; David Lee; Shira Hoschander; Una Hopkins; Dawn Hershman; John J Wright; Celina Kleer; Sofia Merajver; Said M Sebti
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.